Literature DB >> 24294289

Desmopressin in the treatment of nocturia: clinical evidence and experience.

Fara M Friedman1, Jeffrey P Weiss.   

Abstract

Nocturia is a common and bothersome condition experienced by both men and women. Studies have suggested that nocturia contributes a level of morbidity to those who suffer from the condition, both young and old. Desmopressin has historically been utilized to treat conditions such as central diabetes insipidus, certain bleeding disorders and primary nocturnal enuresis. Recently, interest has increased as to the use of desmopressin (a vasopressin analog) in the treatment of adult nocturia, for whom nocturnal polyuria is prevalent. While desmopressin has been traditionally administered in tablet and bioequivalent high dose melt formulations, newer low-dose orally disintegrating sublingual desmopressin has been recently studied to determine safe and efficacious dosing strategies. In this review, nocturia and its associated morbidities are discussed, followed by a contemporary literature review regarding the safety and efficacy of desmopressin for its treatment.

Entities:  

Keywords:  DDAVP; LUTS; desmopressin; nocturia; nocturnal polyuria

Year:  2013        PMID: 24294289      PMCID: PMC3825109          DOI: 10.1177/1756287213502116

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  18 in total

1.  The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society.

Authors:  P Van Kerrebroeck; P Abrams; D Chaikin; J Donovan; D Fonda; S Jackson; P Jennum; T Johnson; G R Lose; A Mattiasson; G L Robertson; J Weiss
Journal:  BJU Int       Date:  2002-12       Impact factor: 5.588

2.  Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study.

Authors:  Haruo Nakagawa; Kaijun Niu; Atsushi Hozawa; Yoshihiro Ikeda; Yasuhiro Kaiho; Kaori Ohmori-Matsuda; Naoki Nakaya; Shinichi Kuriyama; Satoru Ebihara; Ryoichi Nagatomi; Ichiro Tsuji; Yoichi Arai
Journal:  J Urol       Date:  2010-08-19       Impact factor: 7.450

3.  Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study.

Authors:  Chung-Jing Wang; Yu-Nan Lin; Shi-Wei Huang; Chien-Hsing Chang
Journal:  J Urol       Date:  2010-11-13       Impact factor: 7.450

4.  Mortality in older men with nocturia. A 15-year followup of the Krimpen study.

Authors:  Boris van Doorn; Esther T Kok; Marco H Blanker; Paul Westers; J L H Ruud Bosch
Journal:  J Urol       Date:  2012-03-15       Impact factor: 7.450

Review 5.  The prevalence and causes of nocturia.

Authors:  J L H Ruud Bosch; Jeffrey P Weiss
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

6.  Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men.

Authors:  A Mattiasson; P Abrams; P Van Kerrebroeck; S Walter; J Weiss
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

7.  Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years.

Authors:  Hann Chorng Kuo
Journal:  Urology       Date:  2002-04       Impact factor: 2.649

Review 8.  A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis.

Authors:  Jean-Nicolas Cornu; Paul Abrams; Christopher R Chapple; Roger R Dmochowski; Gary E Lemack; Martin C Michel; Andrea Tubaro; Stephan Madersbacher
Journal:  Eur Urol       Date:  2012-07-20       Impact factor: 20.096

9.  Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study.

Authors:  Philip van Kerrebroeck; Masoumeh Rezapour; Ariane Cortesse; Joachim Thüroff; Anders Riis; Jens Peter Nørgaard
Journal:  Eur Urol       Date:  2007-01-16       Impact factor: 20.096

10.  Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women.

Authors:  Gunnar Lose; Othon Lalos; Robert M Freeman; Philip van Kerrebroeck
Journal:  Am J Obstet Gynecol       Date:  2003-10       Impact factor: 8.661

View more
  8 in total

Review 1.  [Treatment of nocturia in men with desmopressin].

Authors:  S Mühlstädt
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

2.  The evaluation and management of persistent nocturia.

Authors:  Dima Raskolnikov; Fara M Friedman; Dhanan J Etwaru; Jeffrey P Weiss
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

Review 3.  Desmopressin for treating nocturia in men.

Authors:  Julia Han; Jae Hung Jung; Caitlin J Bakker; Mark H Ebell; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-10-21

Review 4.  Pharmacotherapy for Nocturia.

Authors:  Karl-Erik Andersson; Philip Van Kerrebroeck
Journal:  Curr Urol Rep       Date:  2018-02-09       Impact factor: 3.092

5.  Mechanistic insights into the slow peptide bond formation with D-amino acids in the ribosomal active site.

Authors:  Sergey V Melnikov; Nelli F Khabibullina; Elisabeth Mairhofer; Oscar Vargas-Rodriguez; Noah M Reynolds; Ronald Micura; Dieter Söll; Yury S Polikanov
Journal:  Nucleic Acids Res       Date:  2019-02-28       Impact factor: 16.971

Review 6.  Korean guideline of desmopressin for the treatment of nocturia in men.

Authors:  Eu Chang Hwang; Hyun Jin Jung; Mi Ah Han; Myung Ha Kim; Seong Hyeon Yu; Hyun Cheol Jeong; Jun Seok Kim; Sung Hyun Paick; Jeong Kyun Yeo; Jae Hung Jung
Journal:  Investig Clin Urol       Date:  2022-09

Review 7.  Nocturia: consequences, classification, and management.

Authors:  Noam D Fine; Jeffrey P Weiss; Alan J Wein
Journal:  F1000Res       Date:  2017-09-01

8.  Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).

Authors:  Marcus J Drake; Luke Canham; Nikki Cotterill; Debbie Delgado; Jenny Homewood; Kirsty Inglis; Lyndsey Johnson; Mary C Kisanga; Denise Owen; Paul White; David Cottrell
Journal:  BMC Neurol       Date:  2018-08-06       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.